WO2019136948A1 - 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒 - Google Patents
一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒 Download PDFInfo
- Publication number
- WO2019136948A1 WO2019136948A1 PCT/CN2018/095067 CN2018095067W WO2019136948A1 WO 2019136948 A1 WO2019136948 A1 WO 2019136948A1 CN 2018095067 W CN2018095067 W CN 2018095067W WO 2019136948 A1 WO2019136948 A1 WO 2019136948A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- myo5a
- protein
- antiphospholipid syndrome
- antibody
- biomarker
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Definitions
- the invention relates to the field of immunotechnology, in particular to an application of an antibody of MYO5A protein as a biomarker for determining antiphospholipid syndrome and a kit thereof.
- APS also known as antiphospholipid syndrome
- Harris EN in 1985 as a major clinical manifestation of recurrent venous thrombosis or habitual abortion with persistent antiphospholipid antibody (APA)-positive syndrome.
- the basic pathological changes are intravascular thrombosis. All kinds of arteriovenous venous thrombosis can cause corresponding symptoms. Small blood vessel thrombosis of placenta can cause miscarriage. Therefore, thrombus is the most prominent clinical manifestation of APS, and it is currently recognized as the main cause of acquired thrombosis.
- Symptoms of APS skin manifestations of reticular leukoplakia, skin ulcers, thrombophlebitis, acral necrosis, reticular leukoplakiosis (Sneddon syndrome), and Behcet's disease and malignant atrophic papulosis-like rash.
- the nervous system can be seen with migraine, chorea, localized cerebral ischemia, lupus-like sclerosis, Jamaican myelopathy (Jamaicanmyelophathy) and Guillain-Barré syndrome.
- Visceral infarction and thrombosis can be seen in cerebral infarction, cerebral venous thrombosis, myocardial infarction, renal infarction, pulmonary infarction, liver Budd-Chiari syndrome, aseptic osteonecrosis, habitual abortion, retinal venous thrombosis and extremity arterial occlusion.
- biomarkers for the determination of antiphospholipid syndrome is necessary for the determination of APS.
- the antibody of the MYO5A protein comprises at least one of IgG, IgM or IgA.
- the above-mentioned antibody of MYO5A protein is used as a biomarker for judging antiphospholipid syndrome for identifying a primary antiphospholipid syndrome.
- Another preferred embodiment of the above-described antibody of MYO5A protein as a biomarker for determining antiphospholipid syndrome is for identifying secondary antiphospholipid syndrome.
- Another preferred embodiment of the above-described antibody of MYO5A protein as a biomarker for determining antiphospholipid syndrome is for simultaneously identifying primary antiphospholipid syndrome and secondary antiphospholipid syndrome.
- the above-mentioned antibody of MYO5A protein is used as a biomarker for determining the antiphospholipid syndrome, and the sequence of the MYO5A protein is
- the present invention also provides a marker which is an antibody produced by the MYO5A protein according to any one of the above, and which detects whether or not an antiphospholipid syndrome is present by detecting the presence or absence of an antibody of the MYO5A protein.
- the present invention also provides a kit which is made of MYO5A protein and which is judged whether or not antiphospholipid syndrome is present by detecting the presence or absence of an antibody of MYO5A protein.
- the MYO5A protein or a partial sequence fragment thereof is selected as a core portion, and the detection method is any one of ELISA, chemiluminescence or POCT.
- the MYO5A protein is used as a core material, and the antibody produced by the kit detects that the target molecule is MYO5A protein, at least one of IgG, IgM or IgA, and the detected sample includes serum, plasma or tissue fluid. .
- the use of the antibody of the MYO5A protein of the present invention as a biomarker for judging antiphospholipid syndrome provides a new marker for discriminating antiphospholipid syndrome, and provides a new application direction for discriminating antiphospholipid syndrome It is of great significance.
- Figure 1 is a graph showing the results of differences in antibodies between the APS group and the disease control group of the MYO5A protein antibody.
- Figure 2 is a graphical representation of the results of significant differences between antibodies to the MY05A protein in the APS group and the healthy control group.
- Figure 3 is a graphical representation of the differences in antibodies to the MY05A protein in the primary APS and secondary APS groups.
- an antibody against the MYO5A protein as a biomarker for the determination of antiphospholipid syndrome.
- the antibody of the MYO5A protein includes at least one of IgG, IgM or IgA.
- the application of the MYO5A protein antibody as a biomarker in the determination of antiphospholipid syndrome can be used to identify primary antiphospholipid syndrome, secondary antiphospholipid syndrome or to simultaneously identify primary antiphospholipid syndrome and secondary Antiphospholipid syndrome.
- the antibody of MYO5A protein was not significantly different between the APS group and the disease control group, as shown in Figure 1.
- the antibody to MY05A protein showed only significant differences between the APS group and the healthy control group, as shown in Figure 2.
- the APS components were divided into primary APS and secondary APS groups in order to find differential protein antibodies between the subgroups.
- the results are shown in Figure 3.
- the results showed that the expression of MYO5A protein antibody was significantly different between the primary APS and the secondary APS group. Moreover, there were significant differences between the primary APS group and other disease control groups and healthy controls.
- the use of the antibody of the MYO5A protein of the present invention as a biomarker for judging antiphospholipid syndrome provides a new marker for discriminating antiphospholipid syndrome, and provides a new application direction for discriminating antiphospholipid syndrome It is of great significance.
- This example provides a marker which is an antibody produced by the MYO5A protein of Example 1, and is judged whether or not the antiphospholipid syndrome is present by detecting the presence or absence of an antibody of the MYO5A protein.
- This embodiment provides a kit which is made of MYO5A protein and which is judged whether or not antiphospholipid syndrome is present by detecting the presence or absence of an antibody of MYO5A protein.
- the kit selects the MYO5A protein or a partial sequence fragment thereof as a core portion, and the detection method is any one of ELISA, chemiluminescence or POCT.
- the kit uses the MYO5A protein as a core material, and the kit detects that the target molecule identified by the MYO5A protein is at least one of IgG, IgM or IgA, and the detected sample includes serum, plasma or tissue fluid.
- the invention utilizes the antibody of MYO5A protein as a biomarker for judging the application of antiphospholipid syndrome, and provides a new marker for discriminating antiphospholipid syndrome, and provides a new kit for discriminating antiphospholipid synthesis The sign is of great significance.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
提供MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用。MYO5A蛋白的抗体包括IgG、IgM或者IgA中的至少一种。可用于鉴别原发和继发性抗磷脂综合征。同时提供一种试剂盒,利用MYO5A蛋白做成,通过检测是否存在MYO5A蛋白的抗体从而判断是否存在抗磷脂综合征。本发明MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用,提供了一种新的判别抗磷脂综合征的标记物,提供了一种新的应用方向,对判别抗磷脂综合征具有重要意义。
Description
本发明涉及免疫技术领域,特别是涉及一种MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用及其试剂盒。
APS,又称抗磷脂综合征,是由Harris EN于1985年最先描述的一组以反复动、静脉血栓或习惯性流产为主要临床表现,伴持续性抗磷脂抗体(APA)阳性的综合征。其基本病理改变为血管内血栓形成,各级动/静脉血管血栓可引起相应症状,胎盘小血管血栓可引起流产,因此血栓是APS最突出的临床表现,是目前公认获得性血栓的主要原因。
APS的症状,皮肤表现可见网状青斑、皮肤溃疡、血栓性静脉炎、肢端坏死、网状青斑性脑血栓形成(Sneddon综合征)以及白塞病和恶性萎缩性丘疹病样皮疹。神经系统可见偏头痛、舞蹈病、局限性脑缺血、狼疮样硬化症、牙买加脊髓病(Jamaicanmyelophathy)及Guillain-Barré综合征。内脏梗塞和血栓形成可见脑梗死、脑静脉血栓、心肌梗死、肾梗塞,肺梗塞、肝Budd-Chiari综合征、无菌性骨坏死、习惯性流产,视网膜动、静脉血栓及四肢动脉闭塞等。
提供生物标记物用于判断抗磷脂综合征对于APS的判断甚为必要。
发明内容
本发明的目的在于提供一种标记物用于判断抗磷脂综合征及其试剂盒。
本发明的上述目的通过如下技术手段实现。
提供MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用。
优选的,MYO5A蛋白的抗体包括IgG、IgM或者IgA中的至少一种。
优选的,上述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用,用于鉴别原发性抗磷脂综合征。
另一优选的,上述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用,用于鉴别继发性抗磷脂综合征。
另一优选的,上述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用,用于同时鉴别原发性抗磷脂综合征和继发性抗磷脂综合征。
优选的,上述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用,MYO5A蛋白的序列为,
本发明同时提供一种标记物,为上述任意一项所述MYO5A蛋白产生的抗体,通过检测是否存在MYO5A蛋白的抗体从而判断是否存在抗磷脂综合征。
本发明同时提供一种试剂盒,利用MYO5A蛋白做成,通过检测是否存在MYO5A蛋白的抗体从而判断是否存在抗磷脂综合征。
进一步的,上述的试剂盒,选择MYO5A蛋白或其部分序列片段作为核心部分,检测方法为ELISA、化学发光法或者POCT法中的任意一种。
进一步的,上述的试剂盒,将MYO5A蛋白作为核心原料,试剂盒检测识别的目标分子为MYO5A蛋白所产生的抗体包括IgG、IgM或者IgA中的至少一种,检测的样本包括血清、血浆或者组织液。
本发明MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用,提供了一种新的判别抗磷脂综合征的标记物,提供了一种新的应用方向,对判别抗磷脂综合征具有重要意义。
利用附图对本发明作进一步的说明,但附图中的内容不构成对本发明的任何限制。
图1是MYO5A蛋白的抗体在APS组和疾病对照组间的差异状况结果图。
图2是MY05A蛋白的抗体在APS组和健康对照组间的显著差异的结果示意图。
图3是MY05A蛋白的抗体在原发APS和继发APS组中的差异情况示意图。
结合以下实施例对本发明作进一步描述。
实施例1。
提供MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用。其中,MYO5A蛋白的抗体包括IgG、IgM或者IgA中的至少一种。
MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用,可用于鉴别原发性抗磷脂综合征、继发性抗磷脂综合征或者同时鉴别原发性抗磷脂综合征和继发性抗磷脂综合征。
MYO5A蛋白的序列为,
下面通过实验对上述结果进行验证说明:
MYO5A蛋白的抗体在APS组和疾病对照组间并没有显著差异,如图1所示。MY05A这个蛋白的抗体只表现出APS组和健康对照组间的显著差异,如图2所示。
将APS组分成原发APS和继发APS组,以期找到亚组之间的差异蛋白抗体,结果如图3,实验发现MYO5A蛋白抗体的表达在原发APS和继发APS组间存在显著差异,而且在原发APS组和其它疾病对照组和健康对照组间均存在显著差异。
本发明MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用,提供了一种新的判别抗磷脂综合征的标记物,提供了一种新的应用方向,对判别抗磷脂综合征具有重要意义。
实施例2。
本实施例提供一种标记物,为通过实施例1的MYO5A蛋白产生的抗体,通过检测是否存在MYO5A蛋白的抗体从而判断是否存在抗磷脂综合征。
实施例3。
本实施例提供一种试剂盒,利用MYO5A蛋白做成,通过检测是否存在MYO5A蛋白的抗体从而判断是否存在抗磷脂综合征。
具体的,该试剂盒,选择MYO5A蛋白或其部分序列片段作为核心部分,检测方法为ELISA、化学发光法或者POCT法中的任意一种。
该试剂盒,将MYO5A蛋白作为核心原料,试剂盒检测识别的目标分子为MYO5A蛋白所产生的抗体包括IgG、IgM或者IgA中的至少一种,检测的样本包括血清、血浆或者组织液。
本发明利用MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用,提供了一种新的判别抗磷脂综合征的标记物,提供了一种新的试剂盒,对判别抗磷脂综合征具有重要意义。
最后应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明作了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的实质和范围。
Claims (10)
- MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用。
- 根据权利要求1所述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用,其特征在于:MYO5A蛋白的抗体包括IgG、IgM或者IgA中的至少一种。
- 根据权利要求2所述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用,其特征在于:用于鉴别原发性抗磷脂综合征。
- 根据权利要求2所述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用,其特征在于:用于鉴别继发性抗磷脂综合征。
- 根据权利要求2所述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用,其特征在于:用于同时鉴别原发性抗磷脂综合征和继发性抗磷脂综合征。
- 一种标记物,其特征在于:为如权利要求1至6任意一项所述MYO5A蛋白产生的抗体,通过检测是否存在MYO5A蛋白的抗体从而判断是否存在抗磷脂综合征。
- 一种试剂盒,其特征在于:利用MYO5A蛋白做成,通过检测是否存在MYO5A蛋白的抗体从而判断是否存在抗磷脂综合征。
- 根据权利要求8所述的试剂盒,其特征在于:选择MYO5A蛋白或其部分序列片段作为核心部分,检测方法为ELISA、化学发光法或者POCT法中的任意一种。
- 根据权利要求8所述的试剂盒,其特征在于:将MYO5A蛋白作为核心原料,试剂盒检测识别的目标分子为MYO5A蛋白所产生的抗体包括IgG、IgM或者IgA中的至少一种,检测的样本包括血清、血浆或者组织液。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/961,263 US20210063415A1 (en) | 2018-01-12 | 2018-07-10 | Applications of biomarker in terms of determining antiphospholipid syndrome and reagent kit of biomarker |
EP18899192.1A EP3734283B1 (en) | 2018-01-12 | 2018-07-10 | Applications of biomarker in terms of determining antiphospholipid syndrome and reagent kit of biomarker |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810030852.3A CN108226534B (zh) | 2018-01-12 | 2018-01-12 | 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒 |
CN201810030852.3 | 2018-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019136948A1 true WO2019136948A1 (zh) | 2019-07-18 |
Family
ID=62640925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/095067 WO2019136948A1 (zh) | 2018-01-12 | 2018-07-10 | 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20210063415A1 (zh) |
EP (1) | EP3734283B1 (zh) |
CN (1) | CN108226534B (zh) |
WO (1) | WO2019136948A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108226534B (zh) * | 2018-01-12 | 2020-06-30 | 广州市康润生物科技有限公司 | 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒 |
CN113884684B (zh) * | 2021-09-10 | 2023-09-15 | 上海依赛洛森生物医药有限公司 | 一种活动性结核病多组学整合标志物、试剂盒及检测模型的构建方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN206489172U (zh) * | 2017-02-16 | 2017-09-12 | 天津市柏艾森生物技术有限公司 | 用于抗磷脂综合征检测的医用采样检测一体化设备 |
CN108226534A (zh) * | 2018-01-12 | 2018-06-29 | 广州市康润生物科技有限公司 | 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2176007A1 (en) * | 1993-11-16 | 1995-05-26 | Eiji Matsuura | Method of assaying antiphospholipid antibody and kit therefor |
US6812327B1 (en) * | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
EP1692519B1 (en) * | 2003-12-03 | 2010-06-02 | Glycominds Ltd. | Method for diagnosing diseases based on levels of anti-glycan antibodies |
IT1396046B1 (it) * | 2009-04-24 | 2012-11-09 | Sorice | Complessi fra fosfolipidi e la proteina vimentina e metodo in vitro per la rilevazione di anticorpi contro detti complessi |
WO2011022780A1 (en) * | 2009-08-27 | 2011-03-03 | South Eastern Sydney And Illawarra Area Health Service | Methods for the diagnosis and prognosis of autoimmune disease |
NZ600909A (en) * | 2009-12-02 | 2014-09-26 | Univ Pretoria | Oligonucleotides and methods for detecting lavender foal syndrome |
US8932810B2 (en) * | 2010-04-23 | 2015-01-13 | Cornell University | Identification of mutation and method for detecting lavender foal syndrome in the horse |
CA2840590C (en) * | 2011-07-01 | 2018-09-04 | Inova Diagnostics, Inc. | Method for increasing specificity of diagnostic tests for autoimmune diseases |
US20190178888A1 (en) * | 2016-01-11 | 2019-06-13 | Technion Research & Development Foundation Limited | Methods of determining prognosis of sepsis and treating same |
ES2642723B1 (es) * | 2016-05-12 | 2018-10-22 | Servizo Galego De Saúde (Sergas) | Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias. |
-
2018
- 2018-01-12 CN CN201810030852.3A patent/CN108226534B/zh active Active
- 2018-07-10 WO PCT/CN2018/095067 patent/WO2019136948A1/zh unknown
- 2018-07-10 EP EP18899192.1A patent/EP3734283B1/en active Active
- 2018-07-10 US US16/961,263 patent/US20210063415A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN206489172U (zh) * | 2017-02-16 | 2017-09-12 | 天津市柏艾森生物技术有限公司 | 用于抗磷脂综合征检测的医用采样检测一体化设备 |
CN108226534A (zh) * | 2018-01-12 | 2018-06-29 | 广州市康润生物科技有限公司 | 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒 |
Non-Patent Citations (3)
Title |
---|
HAN HAIBO ET AL.: "Preparation and identification of mouse anti-human myosin va polyclonal antibody", CHINESE JOURNAL OF CELLULAR AND MOLECULAR IMMUNOLOGY, vol. 25, no. 5, 18 May 2005 (2005-05-18), pages 451 - 453, XP009522459, ISSN: 1007-8738, DOI: 10.13423/j.cnki.cjcmi.005016 * |
See also references of EP3734283A4 * |
VENKAIAH BETAPUDI , GEORGE LOMINADZE , LINDA HSI , BELINDA WILLARD , MEIFANG WU , KEITH R MCCRAE: "Anti-beta 2GPI antibodies stimulate endothelial cell mi-croparticle release via a non-muscle myosin II motor protein-dependent pathway", BLOOD, vol. 122, no. 23, 28 August 2013 (2013-08-28), pages 3808 - 3817, XP055625069, DOI: 10.1182/blood-2013-03-490318 * |
Also Published As
Publication number | Publication date |
---|---|
EP3734283A1 (en) | 2020-11-04 |
EP3734283B1 (en) | 2023-06-14 |
CN108226534B (zh) | 2020-06-30 |
EP3734283C0 (en) | 2023-06-14 |
EP3734283A4 (en) | 2021-03-03 |
US20210063415A1 (en) | 2021-03-04 |
CN108226534A (zh) | 2018-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hanif et al. | Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma | |
JP6655248B2 (ja) | 肝細胞がんマーカー | |
KR101788414B1 (ko) | 간암 조기 진단용 바이오마커 및 그 용도 | |
JP5038407B2 (ja) | 疾患のバイオマーカーとしてのアルブミン結合性タンパク質/ペプチド複合体 | |
JP6669794B2 (ja) | 腎機能の診断若しくは監視又は腎機能障害の診断方法 | |
WO2011015602A2 (en) | Lung cancer biomarkers | |
JP5565607B2 (ja) | 敗血症又は多臓器不全の予後診断方法及び予後診断用キット | |
WO2015182580A1 (ja) | 大腸がんの転移検出方法 | |
Ferrin et al. | Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV‐infected cirrhotic patients by 2‐D DIGE | |
WO2019136948A1 (zh) | 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒 | |
Frantzi et al. | Ten years of proteomics in bladder cancer: progress and future directions | |
JP2010071900A (ja) | 新規非アルコール性脂肪性肝疾患バイオマーカーおよび該バイオマーカーを用いた非アルコール性脂肪性肝疾患の検出方法 | |
WO2021200940A1 (ja) | 血中アミロイドβの免疫測定方法及びそのためのキット | |
JP6829444B2 (ja) | 去勢抵抗性前立腺癌を検出する方法及び検出試薬 | |
JP6757337B2 (ja) | レンバチニブ及びエベロリムスを含む組合せ療法のためのバイオマーカー | |
JP7127422B2 (ja) | 癌を検出する方法及び検出試薬 | |
CN108738347B (zh) | 辅助肝细胞癌患者的再发风险预测的方法、装置、计算机程序制品及试剂盒 | |
US20220236275A1 (en) | Cancer test method | |
US20110256169A1 (en) | Novel polypeptides related to b-type natriuretic peptides and methods of their identification and use | |
EP4189396A1 (en) | Improved epitope for detecting and/or quantifying autoantibodies against alpha-fetoprotein | |
US20210270835A1 (en) | Biomarkers for urothelial carcinoma and applications thereof | |
WO2024124499A1 (zh) | 靶向cxcl4的抗体及其在抑郁障碍诊断中的用途 | |
JP2020514368A5 (zh) | ||
WO2022019298A1 (ja) | 炎症性腸疾患の診断を補助する方法 | |
WO2011090017A1 (ja) | Ku86に対する自己抗体の免疫測定方法、それに用いるキット、及びそれを用いた原発性肝細胞癌の判定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18899192 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018899192 Country of ref document: EP Effective date: 20200812 |